Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J, Nikoskelainen J, Leibl H, Lanbeck P, Wallvik J, Lumio JT, Braconier JH, Pavlova BG, Birthistle K, Engl W, Walter S, Ehrlich HJ. Björkander J, et al. Among authors: engl w. Vox Sang. 2006 May;90(4):286-93. doi: 10.1111/j.1423-0410.2006.00764.x. Vox Sang. 2006. PMID: 16635071 Clinical Trial.
Rapid subcutaneous immunoglobulin administration every second week results in high and stable serum immunoglobulin G levels in patients with primary antibody deficiencies.
Gustafson R, Gardulf A, Hansen S, Leibl H, Engl W, Lindén M, Müller A, Hammarström L. Gustafson R, et al. Among authors: engl w. Clin Exp Immunol. 2008 May;152(2):274-9. doi: 10.1111/j.1365-2249.2008.03620.x. Epub 2008 Mar 12. Clin Exp Immunol. 2008. PMID: 18341618 Free PMC article.
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease.
Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, Engl W, Leibl H, Sobolevsky L, Gelmont D, Schiff RI, Grossman WJ. Wasserman RL, et al. Among authors: engl w. J Clin Immunol. 2011 Jun;31(3):323-31. doi: 10.1007/s10875-011-9512-z. Epub 2011 Mar 22. J Clin Immunol. 2011. PMID: 21424824 Clinical Trial.
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 Study Group. Wasserman RL, et al. Among authors: engl w. J Allergy Clin Immunol. 2012 Oct;130(4):951-7.e11. doi: 10.1016/j.jaci.2012.06.021. Epub 2012 Jul 28. J Allergy Clin Immunol. 2012. PMID: 22846381 Clinical Trial.
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.
Wasserman RL, Melamed I, Stein MR, Engl W, Sharkhawy M, Leibl H, Puck J, Rubinstein A, Kobrynski L, Gupta S, Grant AJ, Ratnayake A, Richmond WG, Church J, Yel L, Gelmont D. Wasserman RL, et al. Among authors: engl w. J Clin Immunol. 2016 Aug;36(6):571-82. doi: 10.1007/s10875-016-0298-x. Epub 2016 May 25. J Clin Immunol. 2016. PMID: 27220317 Free PMC article. Clinical Trial.
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, Sharkhawy M, Engl W, Leibl H, Gelmont D, Yel L. Wasserman RL, et al. Among authors: engl w. Immunotherapy. 2016 Oct;8(10):1175-86. doi: 10.2217/imt-2016-0066. Epub 2016 Jul 28. Immunotherapy. 2016. PMID: 27468136 Free article. Clinical Trial.
Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M, Kriván G, Derfalvi B, Maródi L, Harrer T, Jolles S, Bourgeois C, Engl W, Leibl H, McCoy B, Gelmont D, Yel L. Borte M, et al. Among authors: engl w. Clin Exp Immunol. 2017 Jan;187(1):146-159. doi: 10.1111/cei.12866. Epub 2016 Oct 18. Clin Exp Immunol. 2017. PMID: 27613250 Free PMC article. Clinical Trial.
62 results